The FDA and Novartis have notified healthcare professionals that the WARNINGS and ADVERSE REACTIONS sections of the Myfortic (mycophenolic acid delayed-release tablets) Prescribing Information have been updated to include cases of pure red cell aplasia (PRCA) that have been reported in patients treated with Myfortic in combination with other immunosuppressive agents.

Myfortic is an immunosuppressant indicated for organ rejection prophylaxis in allogeneic renal transplant patients, in combination with cyclosporine and corticosteroids.

For more information visit www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM181308.pdf.